Changes in ratio of ineligible use of lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency.

Autor: Usui K; Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan.; Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan., Yamada K; Division of Psychiatry, Tohoku Medical and Pharmaceutical University, Sendai, Japan., Okada K; Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan.; Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan., Ouchi R; Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan.; Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan., Nibuya M; Division of Psychiatry, Tohoku Medical and Pharmaceutical University, Sendai, Japan., Takahashi A; Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan., Shito Y; Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan., Watanabe Y; Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, Sendai, Japan.; Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan., Saeki H; Department of Dermatology, Nippon Medical School, Tokyo, Japan., Suzuki E; Division of Psychiatry, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Jazyk: angličtina
Zdroj: Psychiatry and clinical neurosciences [Psychiatry Clin Neurosci] 2021 Jan; Vol. 75 (1), pp. 27-28. Date of Electronic Publication: 2020 Oct 12.
DOI: 10.1111/pcn.13156
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje